Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 9.30B +128.3% |
| Revenue (ttm) | 281.99M +34.8% |
| Net Income | 82.91M +59.3% |
| EPS | 1.22 +51.8% |
| Shares Out | 64.71M |
| PE Ratio | 117.70 |
| Forward PE | 70.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 763,092 |
| Open | 139.91 |
| Previous Close | 139.91 |
| Day's Range | 138.95 - 146.30 |
| 52-Week Range | 65.56 - 160.81 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 174.69 (+21.54%) |
| Est. Earnings | Nov 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $174.69, which is an increase of 21.54% from the latest price.
News
Protagonist Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Two first-in-class peptide drugs were recently approved, driving strong financials and a $300M share buyback. The pipeline includes oral IL-17 and IL-4 blockers, with a focus on chronic indications and scalable obesity treatments. R&D is prioritized, with flexibility to partner or advance assets independently.
Protagonist Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
Two drugs were approved this year, including MIMRYLO for PV, with strong commercial launches and robust pharma partnerships driving revenue and R&D. The pipeline focuses on oral peptide therapeutics targeting chronic diseases, with strategic plans for asset retention, partnerships, and early clinical milestones in obesity and rare diseases.
Protagonist Therapeutics announces $300M share repurchase program
Protagonist Therapeutics (PTGX) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $300M of its outstanding common stock. The…
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Co...
Protagonist Therapeutics Slides: Corporate presentation
Protagonist Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $190 from $178 and keeps an Outperform rating on the shares. The firm notes that…
Protagonist Therapeutics price target raised to $180 from $153 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Protagonist Therapeutics (PTGX) to $180 from $153 and keeps an Overweight rating on the shares. The firm believes FDA approval…
Protagonist Therapeutics price target raised to $182 from $175 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Protagonist Therapeutics (PTGX) to $182 from $175 and keeps a Buy rating on the shares. The firm views FDA approval…
Protagonist Therapeutics price target raised to $170 from $165 at Citizens
Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $170 from $165 and keeps an Outperform rating on the shares after the FDA approved rusfertide for erythrocytosis in…
Protagonist Therapeutics Transcript: FDA announcement
FDA approved MIMRYLO (rusfertide) for erythrocytosis in polycythemia vera, offering a first-in-class, well-tolerated therapy with a broad label. The drug demonstrated strong efficacy and safety in clinical trials, is expected to shift the PV treatment paradigm, and will be commercialized by Takeda.
Protagonist Therapeutics Press release: FDA announcement
Protagonist Therapeutics issued a press release on August 31, 2026, disclosing material business information to investors.
Protagonist Therapeutics Slides: FDA announcement
Protagonist Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 31, 2026.
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $170 from $167 and keeps a Buy rating on the shares after Protagonist announced the FDA approval of…
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously delivered first-in-class hepcidin mimetic peptide fo...
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control...
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in ac...
Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital
BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $178 from $112 and keeps an Outperform rating on the shares. The firm notes that the Icotyde initial…
Protagonist Therapeutics price target raised to $170 from $145 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $170 from $145 and keeps a Buy rating on the shares as part of a broader…
Protagonist Therapeutics price target raised to $173 from $118 at Wedbush
Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $118 and keeps an Outperform rating on the shares. The firm cites last week’s Q2 update, based…
Protagonist Therapeutics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Richard Law upgraded Protagonist Therapeutics (PTGX) to Buy from Neutral with a price target of $186, up from $110, following the Q2 report. Given the favorable Phase…
Protagonist Therapeutics price target raised to $175 from $130 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Protagonist Therapeutics (PTGX) to $175 from $130 and keeps a Buy rating on the shares post the Q2 report. The…
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $116 and keeps a Buy rating on the shares post the Q2 report.
Protagonist Therapeutics price target raised to $153 from $151 at Barclays
Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $153 from $151 and keeps an Overweight rating on the shares.
Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93
Reports Q2 revenue $213.48M, consensus $223.17M. “The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner...